Table 3. Stratification Analysis Of Risk Genotypes With Neuroblastoma Susceptibility.

Variables	rs110419(cases/controls)		OR	P	Adjusted OR a	Pa	Combined		OR	P	Adjusted ORa	Pa
	AA	AG/GG	(95% CI)		(95% CI)		0–3	4	(95% CI)		(95% CI)
Age, month
≤ 18	37/74	64/159	0.81 (0.49–1.31)	0.386	0.80 (0.49–1.31)	0.378	88/187	13/46	0.60 (0.31–1.17)	0.134	0.59 (0.30–1.16)	0.124
> 18	66/85	89/213	0.54 (0.36–0.81)	0.003	0.54 (0.36–0.80)	0.003	142/248	13/50	0.45 (0.24–0.87)	0.016	0.45 (0.24–0.86)	0.015
Gender
Females	43/73	60/160	0.64 (0.39–1.03)	0.065	0.64 (0.40–1.03)	0.068	92/199	11/34	0.70 (0.34–1.44)	0.334	0.71 (0.34–1.46)	0.346
Males	60/86	93/212	0.63 (0.42–0.95)	0.027	0.63 (0.42–0.95)	0.026	138/236	15/62	0.41 (0.23–0.76)	0.004	0.42 (0.23–0.76)	0.004
Sites of origin
Adrenal gland	25/159	21/372	0.36 (0.20–0.66)	0.001	0.36 (0.19–0.66)	0.001	42/435	4/96	0.43 (0.15–1.23)	0.117	0.43 (0.15–1.24)	0.117
Retroperitoneal	26/159	61/372	1.00 (0.61–1.65)	0.991	1.00 (0.61–1.65)	0.993	76/435	11/96	0.66 (0.34–1.28)	0.217	0.65 (0.33–1.27)	0.203
Mediastinum	38/159	52/372	0.59 (0.37–0.92)	0.022	0.59 (0.37–0.93)	0.024	85/435	5/96	0.27 (0.11–0.68)	0.005	0.27 (0.11–0.68)	0.006
Others	12/159	13/372	0.46 (0.21–1.04)	0.061	0.46 (0.20–1.03)	0.058	23/435	2/96	0.39 (0.09–1.70)	0.212	0.37 (0.09–1.61)	0.185
Clinical stage
I + II + 4s	46/159	80/372	0.74 (0.50–1.12)	0.154	0.74 (0.49–1.11)	0.140	115/435	11/96	0.43 (0.23–0.84)	0.013	0.42 (0.22–0.82)	0.010
III + IV	52/159	69/372	0.57 (0.38–0.85)	0.006	0.56 (0.37–0.84)	0.005	107/435	14/96	0.59 (0.33–1.08)	0.087	0.61 (0.33–1.12)	0.108

^aAdjusted for age and gender.